The Ebola virus has penetrated U.S. borders, and small biotech firms are racing to develop a cure. That being said, biotech sector trading volumes over the last two weeks have risen to unprecedented levels; moreover, nearly all Ebola-centric biotech stocks have generated impressive returns to match this rise in trading volume.